After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs, some U.S.

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

(Reuters) -After years of easily available, cheap copies of Eli Lilly's and Novo Nordisk's highly effective weight-loss drugs ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

The Cigna Group (NYSE: CI )’s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Viking Therapeutics has key trial catalysts ahead and trades near biotech deal valuations, despite dilution risks. Find out ...